We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Beacons Technology Used in Rapid COVID-19 Tests

By LabMedica International staff writers
Posted on 22 Apr 2020
Print article
Image: Fred Russell Kramer, professor of microbiology, biochemistry and molecular genetics at New Jersey Medical School (Photo courtesy of Rutgers University)
Image: Fred Russell Kramer, professor of microbiology, biochemistry and molecular genetics at New Jersey Medical School (Photo courtesy of Rutgers University)
The molecular beacons technology invented by researchers at Rutgers University (New Brunswick, NJ, USA) will be used in about 50,000 COVID-19 tests produced per day by Abbott (Lake Forest, IL, USA). Abbott’s COVID-19 rapid test, which has received Food and Drug Administration (FDA) emergency use authorization, includes the molecular beacons technology that has been invented and perfected by Rutgers scientists over the last decade. The test, which uses a nose swab, takes less than 15 minutes to complete and can determine if the virus has invaded a cell, taken over its molecular machinery and is making new viruses.

The technology provides powerful tools for imaging RNA in living cells and can determine if COVID-19 is present in a clinical sample. Molecular beacons can bind to a target nucleic acid if it is present in the test solution. If COVID-19 RNA is detected, the molecular beacons wrap themselves around the amplified target nucleic acids, which provide a blueprint of what is occurring in cells, changing their shape and shining a light to signal the presence of the virus.

Molecular beacons are added to the solutions in which clinical assays are carried out, and the reaction tubes are sealed before amplification of the target occurs. The test tubes are never opened again and the only things that leave the test tube are the differently colored fluorescent signals that indicate which target molecules are present. By virtue of the time it takes to generate those signals, the results indicate how abundant the different targets were in the original sample. Since the test tubes remain sealed, the amplified targets cannot escape to contaminate samples that have not yet been tested.

“As molecular diagnostic researchers, it is gratifying when you can help improve lives in a meaningful way, especially during times like these amid a global pandemic,” said Fred Russell Kramer, professor of microbiology, biochemistry and molecular genetics, Public Health Research Institute, New Jersey Medical School.


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.